Xenon Pharmaceuticals Inc. (XENE) income statement
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$37.75−1.03 (-2.66%)
Close on Nov 18, 2026Market cap $3.66BP/E –Yield –
Xenon Pharmaceuticals Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -51.8%
Financial strength
- Current ratio
- 21.02
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 265.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.94
- Dividend yield
- –
See a number that looks wrong?